Definium Therapeutics
About Definium Therapeutics
Definium Therapeutics is a clinical-stage biopharmaceutical company developing neuroplastogen-based therapies for psychiatric and neurological disorders. Its operating model centers on advancing proprietary drug candidates through clinical development, regulatory review, and commercialization. The company's pipeline is led by DT120, an orally administered therapy in Phase 3 clinical trials for generalized anxiety disorder and major depressive disorder, alongside DT402 for autism spectrum disorder. Definium also develops treatment protocols and care delivery models designed to support administration of its therapies. Its strategic focus is on building a portfolio of treatments intended to address the underlying causes of brain health disorders through neuroplasticity-based mechanisms.
Definium Therapeutics Raises Mega Funding Round To Advance LSD Drug
Definium Therapeutics (NASDAQ: DFTX) has successfully raised $805 million in a new equity financing round at a price of $34.00 per share.
MindMed Is Now Dosing Patients In Phase III Clinical Trial For LSD
MindMed (NASDAQ: MNMD) has officially begun dosing the first patients in their Phase III clinical trial for MM120 ODT for the treatment of generalized anxiety.
MindMed Receives Breakthrough Therapy Designation From FDA For LSD
Psychedelic biotechnology company MindMed (NASDAQ: MNMD) has received a Breakthrough Therapy designation from the United States FDA for their novel drug MM120.
